The trial, which is the first to be implemented under Operation Warp Speed, is expected to enroll around 30,000 adults and will be conducted at multiple clinical research sites across the US.
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
Use supported regardless of BRAF V600E/K mutation status, receipt of prior BRAFi with/without MEKi.
For patients receiving HLA-matched sibling donor transplantation, antithymocyte globulin can reduce the incidence of acute graft-vs-host-disease.
Nurse-led posttreatment care at a lower frequency did not negatively affect care or patient satisfaction with their care.
A retrospective study found similar efficacy and toxicity outcomes among patients with refractory DLBCL who were treated with axi-cel outside of trial inclusion criteria.
This analysis focused on QoL end points associated with different dosing schedules for first-line carboplatin-paclitaxel in a predominantly European population with EOC.
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the Food and Drug Administration.
Prospective study shows increased risk for esophageal, gastric adenocarcinoma in two large cohorts.
Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.
Please login or register first to view this content.
